Medical school professor Bryant Lin's insurance company denied approval for Rybrevant, a drug used to treat stage 4 cancer.

The medtech firm is using Nvidia’s technology in its Monarch robotic platform for urology.

Johnson & Johnson MedTech (NYSE: JNJ) today announced new advances in surgical robotic technology with physical AI ...

Freedom Capital analyst Ilya Zubkov raised the firm’s price target on Intuitive Surgical (ISRG) to $560 from $475 and keeps a Hold rating on the ...